Orexin Antagonists (Dayvigo, Quviviq) for Post-Injury Insomnia

Amar Lunagaria — Co-Founder & Chief Pharmacist, LienScripts | March 26, 2026 | 8 min read

Orexin receptor antagonists like lemborexant (Dayvigo) and daridorexant (Quviviq) represent the newest class of sleep medications for post-injury insomnia. Learn their clinical profile and implications for personal injury cases.

Orexin Antagonists (Dayvigo, Quviviq) for Post-Injury Insomnia

Orexin receptor antagonists — including lemborexant (Dayvigo), daridorexant (Quviviq), and suvorexant (Belsomra) — are the newest class of FDA-approved sleep medications and work by blocking the orexin neuropeptides that promote and maintain wakefulness. When prescribed after a traumatic injury, these medications represent a significant escalation in insomnia treatment that documents refractory sleep disruption unresponsive to first-line agents, making them powerful evidence of injury-related sleep impairment in personal injury cases.

• Orexin antagonists block orexin-A and orexin-B neuropeptides (also called hypocretin) that drive the wake-promoting system in the lateral hypothalamus
• FDA approved lemborexant (Dayvigo) in 2019 and daridorexant (Quviviq) in 2022 for insomnia characterized by difficulty with sleep onset and maintenance
• These agents are prescribed after first-line options (trazodone, hydroxyzine) and second-line options (zolpidem, eszopiclone) have proven inadequate
• LienScripts generates a MERIT (Medication Evaluation & Rationale for Injury Treatment) report documenting the clinical escalation pathway that led to orexin antagonist prescribing
• The prescription of an orexin antagonist after an accident documents severe, treatment-resistant insomnia that strengthens the demand narrative

How Orexin Antagonists Work

The orexin (hypocretin) system is a wake-promoting circuit centered in the lateral hypothalamus. Two neuropeptides — orexin-A and orexin-B — bind to OX1 and OX2 receptors throughout the brain to maintain wakefulness and alertness. This system is distinct from the GABA-based sedation pathway targeted by benzodiazepines and Z-drugs (zolpidem, eszopiclone).

Orexin antagonists work by blocking these receptors, effectively reducing the biological drive to stay awake rather than forcibly inducing sedation. This mechanism produces more physiological sleep architecture compared to traditional hypnotics (FDA label, NDA 212028 for lemborexant; NDA 214985 for daridorexant).

Key distinction: Traditional sleep medications push the brain toward unconsciousness. Orexin antagonists remove the barrier to natural sleep onset. This difference in mechanism means orexin antagonists preserve more normal sleep stages and are associated with fewer next-day cognitive effects.

[!KEY] Orexin antagonists work by blocking the brain's wake-promoting system rather than sedating it — this mechanistic difference makes them appropriate for injury-related insomnia where hyperarousal and sympathetic activation keep the patient in a persistent wake state that traditional sedatives cannot adequately overcome.

Clinical Profiles of Available Agents

Lemborexant (Dayvigo)

• FDA approval: December 2019 for insomnia (sleep onset and maintenance)
• Dosing: 5 mg at bedtime; may increase to 10 mg
• Half-life: ~17-19 hours (dual OX1/OX2 antagonist)
• Schedule: Schedule IV controlled substance
• Key trial data: SUNRISE-1 and SUNRISE-2 trials demonstrated superiority over placebo for both sleep onset and maintenance in adults (PubMed PMID: 31006560)

Daridorexant (Quviviq)

• FDA approval: January 2022 for insomnia (sleep onset and maintenance)
• Dosing: 25-50 mg at bedtime
• Half-life: ~8 hours (shorter than lemborexant, reducing next-day effects)
• Schedule: Schedule IV controlled substance
• Key trial data: Phase 3 trials demonstrated improvement in both objective sleep parameters and daytime functioning (PubMed PMID: 35025073)

Suvorexant (Belsomra)

• FDA approval: August 2014 (first-in-class)
• Dosing: 10-20 mg at bedtime
• Half-life: ~12 hours
• Key consideration: The original orexin antagonist; lemborexant and daridorexant offer improved selectivity profiles

[!TIP] Daridorexant's shorter half-life makes it particularly relevant for PI cases where the patient needs to function during the day — its prescription specifically addresses both nighttime insomnia and daytime impairment, documenting both dimensions of the sleep disruption injury.

Why Orexin Antagonist Prescribing Matters in PI Cases

Documents Treatment Failure Cascade

Orexin antagonists are not first-line sleep medications. Before prescribing one, the treating physician has typically tried:

1. Sleep hygiene counseling — behavioral interventions
2. Trazodone or hydroxyzine — first-line pharmacotherapy
3. Zolpidem or eszopiclone — second-line hypnotics
4. The orexin antagonist — third-line or later

Each step in this cascade is a documented treatment failure. By the time a patient reaches an orexin antagonist, the medical record contains multiple physician assessments concluding that prior treatments were inadequate.

According to James Wong, PharmD, founder of LienScripts, "An orexin antagonist prescription is at least a third-line sleep medication. The physician has already tried simpler, cheaper options and documented their failure. This escalation pathway is some of the strongest pharmacological evidence of genuine, severe post-traumatic insomnia."

Documents a Specific Neurobiological Mechanism

The orexin system is specifically implicated in trauma-related hyperarousal. Research shows that traumatic stress can dysregulate orexin signaling, leading to persistent wakefulness and hypervigilance (PubMed PMID: 30798977). Prescribing an orexin antagonist signals the physician has identified a hyperarousal-driven insomnia pattern consistent with post-traumatic pathophysiology.

High Cost Signals Clinical Conviction

Orexin antagonists are branded medications that cost significantly more than generic alternatives. Physicians do not prescribe them casually. The prescribing decision reflects clinical conviction that the patient's insomnia is severe enough to warrant the most targeted available therapy.

[!KEY] An orexin antagonist prescription documents at least two prior treatment failures, identifies hyperarousal-driven insomnia consistent with trauma, and reflects a physician's clinical conviction that the sleep disruption is severe enough to warrant the most targeted available pharmacotherapy.

Documentation for Demand Packages

The LienScripts MERIT report for cases involving orexin antagonists documents:

1. The complete sleep medication timeline — from first sleep medication prescribed to the orexin antagonist
2. Each treatment failure — dates and agents that proved inadequate
3. The escalation rationale — why the physician moved to an orexin antagonist
4. Duration of therapy — how long the orexin antagonist was needed
5. Clinical context — the relationship between the accident, sleep disruption, and the prescribing cascade

As Amar Lunagaria, PharmD, LienScripts' Chief Pharmacist explains, "When an orexin antagonist appears on a pharmacy lien, we know this patient has severe post-traumatic insomnia. The MERIT report maps the entire escalation pathway so the attorney can present the sleep disruption as a thoroughly documented, objectively treated injury component."

Safety Profile and Considerations

Orexin antagonists have a generally favorable safety profile compared to older hypnotics:

• Lower abuse potential than benzodiazepines (still Schedule IV but mechanistically distinct)
• Preserved sleep architecture — more natural sleep stage distribution than Z-drugs
• Fewer next-day cognitive effects — particularly daridorexant with its shorter half-life
• No respiratory depression — unlike benzodiazepines, safe in patients with mild sleep apnea
• Most common side effects: somnolence, headache, dizziness (FDA prescribing information)

The main clinical concern is sleep paralysis and hypnagogic hallucinations, which occur rarely but should be documented if present, as they add to the injury burden.

Adjuster Objections and Responses

"This is an expensive brand-name medication when generics are available." Counter: Orexin antagonists have no generic equivalents because they are a new drug class. The physician prescribed this agent specifically because generic sleep medications (trazodone, zolpidem) failed to adequately treat the patient's insomnia. There is no cheaper equivalent with the same mechanism of action.

"The patient just needs to practice better sleep habits." Counter: The prescribing physician has already addressed behavioral sleep interventions. Pharmacological escalation to an orexin antagonist indicates the insomnia has a neurobiological basis — specifically hyperarousal-driven orexin dysregulation — that behavioral approaches alone cannot resolve.

"Sleep medications should not be on a pharmacy lien." Counter: Post-traumatic insomnia is a direct consequence of the injury that impairs healing, increases pain sensitivity, reduces work capacity, and worsens emotional distress. Treating it is as clinically necessary as treating pain or inflammation.

Pharmacy Lien Access for Orexin Antagonists

Orexin antagonists are expensive branded medications that face insurance prior authorization requirements and high copays. A pharmacy lien through LienScripts ensures patients receive these clinically indicated medications without financial barriers or insurance-imposed delays, while generating the dispensing documentation needed for the demand package.

Related Resources

• Sleep Disruption After an Accident: Medication as Evidence
• PTSD Medication Stacking Strategy
• Pain Management After a Car Accident
• How LienScripts Works